Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Research by UC Irvine immunologists reveals ... light on a vital process that determines how the ... online version of Nature Immunology , neurology professor ... Institute for Immunology colleagues describe a critical mechanism underlying ... the bloodstream. , A T cell is a type ...
(Date:9/30/2014)... A University of Maryland-led research team has been ... National Institutes of Health (NIH) to develop new ... further our understanding of how large networks of ... information. This knowledge will help researchers identify the ... drive behavior, like decision-making and speaking, and alterations ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 EverStryke ... a free introduction to SurvivalLife.com along with a free book ... the attention of Shane Michaels, prompting an investigative review. ... well-known people in the survival and preparation niche, and this ... of the great classes and survival products that Joe offers ...
(Date:9/30/2014)... Elevate , the latest product from ... and out of the gym by providing natural ingredients that ... of Shane Michaels, prompting an investigative review. , “When ... most people simply just don’t have the ability to perform ... work, getting the motivation to finish a project, or even ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... providers in Turkey has gone up more than 79 ... The medical tourism company also reported total revenue tripled ... 2012. , The company’s professional strategy has allowed them ... — ultimately designed for patient comfort and privacy — ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... The Disc-Traction ... Therapeutic Belt., LAGUNA BEACH, Calif., Nov. 15 ... little stresses on their,shoulders all year round? Perhaps something designed to ease ... lower back,pain, whether during the holiday season or any other time of ...
... and CHIPPENHAM, England, November 15, Sosei Group ... Group plc ("Vectura"; LSE: VEC) announce the,start, ... study of QVA149 for the treatment,of chronic ... combination of,NVA237, a once-daily long-acting muscarinic antagonist ...
... the United States has health insurance is essential, but ... reform the health system needs, according to a new ... a High Performance Health System. , Guaranteeing affordable health ... health care providers are paid, better organizing and coordinating ...
... Some 225 healthcare,organizations, representing a broad industry spectrum, ... presentation in Las Vegas on,November 4 during the ... eHealthcare Leadership Awards were selected from more,than 1,100 ... healthcare and,the Internet judged the entries. The ...
... Corporation and its former outpatient therapy division,Physiotherapy ... United States $16.6,million to settle allegations that ... federal health care programs, the Justice Department,announced ... Physiotherapy, which is based,in Memphis, Tenn., submitted ...
... holiday season certainly comes,with its share of holiday stress. ... young son or daughter. Here,s more on the difficult ... who has diabetes. Listen to this report from ... Registered journalists can access video, audio, text, graphics ...
Cached Medicine News:Health News:Eliminate Holiday Aches and Pains: The Perfect Gift for Every Back Pain Sufferer on Your List 2Health News:Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD 2Health News:Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD 3Health News:Commonwealth Fund Commission issues reform recommendations for next president 2Health News:Commonwealth Fund Commission issues reform recommendations for next president 3Health News:Epilepsy.com Wins Silver for Best Patient Care/Disease Management Website at the 2007 eHealthcare Leadership Awards - Honored at Healthcare Internet Conference in Las Vegas 2Health News:Stryker Corp. & Physiotherapy Associates to Pay U.S. $16.6 Million for Alleged False Claims to Federal Health Care Programs 2
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... allows Kessler Foundation and New Jersey Health Foundation ... education and patient care programs has been announced ... executive officer of Kessler Foundation and James ... Foundation. "The experience of New Jersey ...
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional ... towels and tissue for a wide range of ... of its product lines in healthcare, including hospitals, ... Georgia-Pacific Professional is introducing its healthcare products and ... Professional understands the importance of infection control in ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Toothed pituitary rongeur....
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective....
Bayonet Kerrison Rongeur, ceramic ejector, 9.5 length 40 Fwd, 6.5 working length 165 mm....
Medicine Products: